Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OVI 237

Drug Profile

OVI 237

Alternative Names: 1843U89; BW 1843U89; GS 7904L; GW 1843U89; Liposomal OSI 7904; OSI-7904L; OVI-237

Latest Information Update: 16 Jun 2011

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OSI Pharmaceuticals
  • Developer OncoVista
  • Class Antimalarials; Antineoplastics
  • Mechanism of Action Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Biliary cancer; Cancer; Malaria

Most Recent Events

  • 31 Mar 2011 Discontinued - Phase-II for Cancer in USA (unspecified route)
  • 06 Dec 2007 OSI 7904L licensed to OncoVista worldwide
  • 31 May 2004 Phase-II clinical trials in Biliary cancer in Europe (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top